SEARAINBOW(000503)2025-01-22 08:30Financial Performance - The company expects a net loss of approximately RMB 20 million for the fiscal year 2024, a significant improvement from a loss of RMB 79.79 million in the previous year, representing a reduction in loss of 75%[3] - Operating revenue is projected to be around RMB 350 million, reflecting a year-on-year growth rate of approximately 6% compared to RMB 330.13 million in the previous year[3] - The net profit attributable to shareholders is expected to be a loss of RMB 14.6 million after deducting non-recurring gains and losses, compared to a loss of RMB 11.58 million in the previous year[3] - The basic earnings per share is projected to be a loss of RMB 0.0204, improving from a loss of RMB 0.0876 per share in the previous year[3] Investment and Income - The company realized approximately RMB 130 million in investment income from the sale of 18.96% equity in Hainan Haihong Chemical Fiber Co., Ltd. and 45% equity in Guangdong Haihong Pharmaceutical E-commerce Co., Ltd.[6] Strategic Focus - The company is focusing on a strategic plan centered around "three medical collaborations, innovation-driven, and digital ecology" to enhance its service capabilities and market position[5] - The company is increasing investments in digital healthcare and digital health to continuously optimize and improve its product system[5] - The company emphasizes the importance of digital medical and pharmaceutical services to maintain its industry-leading position[5] Caution and Disclosure - The financial data in the earnings forecast has not been audited by registered accountants, and investors are advised to exercise caution[7] - The specific financial data for the fiscal year 2024 will be disclosed in detail in the annual report[7]